Meperidina

Quick links to important sections

Meperidina

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meperidina

Meperidine: Defining the Synthetic Opioid Class

Property Description
Active ingredient Meperidine hydrochloride
Form Injectable solution, Tablet, Oral solution
Pharmacological class Opioid analgesic / Narcotic
Common use Relief of moderate to severe pain
Origin Synthetic (Piperidine derivative)

Meperidine, widely recognized as Pethidine internationally, is a chemically manufactured substance classified as a synthetic narcotic analgesic used exclusively for relief from moderate to severe pain. The core component is Meperidine hydrochloride, a single-ingredient compound derived from the piperidine chemical structure. Its synthetic origin distinguishes it from natural opioids, which are derived from plant sources. The substance is clinically recognized for its role in acute pain management, particularly in operative and obstetric settings, and is recognized as an essential medicine for providing effective pain management.


Forms, Composition, and General Function

Meperidine is primarily formulated as a solution for injection in an aqueous base, although it is also available in tablet and oral solution forms, allowing for either parenteral or oral administration. The drug's composition as a single active compound ensures a focused effect tied directly to its specific pharmacological class: a potent \mu-opioid receptor agonist. Meperidine's mechanism targets central receptors for effective analgesia. The general therapeutic purpose is to effectively modify how the central nervous system processes pain signals, which is why it is utilized for profound pain mitigation, such as after major surgical procedures.


Why is Meperidine Classified as a Narcotic?

Meperidine is classified as a narcotic because it acts as a central nervous system depressant and possesses the potential for dependence, necessitating its stringent control and prescription-only status. This categorization identifies the drug's powerful effect on the brain and spinal cord, where it dampens nervous activity to block the perception of pain signals. While the term "narcotic" is often used in regulatory contexts, its pharmacological identity is defined by its potent and selective action within the opioid receptor system.

What side effects are possible with Meperidina?

Possible side effects and safety information

The official safety profile for meperidine (pethidine) details adverse reactions across several physiological systems, as documented by government regulatory agencies. The most Common effects, categorized under Nervous System and Gastrointestinal Disorders, include sedation, dizziness, nausea, vomiting, and constipation.


Serious Adverse Reactions

Regulatory documentation highlights serious adverse reactions that are potentially life-threatening. The primary concern is Respiratory Depression, which is a significant, dose-related risk. Furthermore, the drug's active metabolite, normeperidine, can accumulate, especially with prolonged use or high doses, leading to CNS toxicity and seizures.

Serotonin Syndrome is officially listed as a rare but potentially fatal risk when meperidine is used concurrently with Monoamine Oxidase Inhibitors (MAOIs). This severe safety risk establishes an absolute contraindication against concurrent use or use within 14 days of receiving an MAOI.


Population and Exposure Safety Patterns

The label includes specific safety considerations for certain patient groups. Older adults may have an increased risk of CNS effects and respiratory depression due to altered drug clearance. Patients with renal impairment face a heightened risk of normeperidine accumulation and associated seizures.

Regarding duration, the regulatory profile notes that physical dependence and drug tolerance are associated with repeated or long-term administration. The risk of CNS toxicity from normeperidine increases with the duration of use and cumulative exposure to the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents characterize Meperidine overdose by two primary toxic effects: severe CNS and Respiratory Depression and unique Excitatory Neurotoxicity.

Documented Overdose Manifestations

Classification Manifestations and Signs
CNS & Respiratory Somnolence progressing to coma or loss of consciousness; life-threatening respiratory depression (slow/shallow breathing, apnea); circulatory collapse; and cyanosis (bluish skin)
Neurotoxicity Convulsions (seizures), tremors, and hyperactive reflexes caused by the accumulation of the active metabolite, normeperidine

Required Emergency Actions

Official labeling mandates that immediate medical attention must be sought for any suspected overdose, particularly if signs such as slowed breathing, the inability to be awakened, or seizures occur. Overdose is considered life-threatening and potentially fatal.

The required immediate response includes calling emergency services and the prompt administration of an opioid antagonist, such as Naloxone, as the specific antidote for respiratory effects. Additionally, emergency measures include the reestablishment of a patent airway and the institution of assisted or controlled ventilation.

Therapeutic Uses of Meperidina

Meperidine (Pethidine) is used to provide symptomatic relief and offers supportive therapeutic benefit across key clinical domains marked by heightened patient distress. Its primary applications revolve around acute pain and procedural support.

The medication is commonly used to address intense and pervasive moderate to severe pain manifestations, which may appear suddenly, such as those following surgical procedures or during medical interventions. The benefit involves providing supportive analgesia that may help make acute and painful episodes easier to tolerate, contributing to overall patient comfort during these challenging phases. It is commonly used in settings where symptoms require symptomatic support, including as a preoperative adjunct to anesthesia, for obstetrical analgesia during labor, and for easing severe physical stress reactions like shaking chills or rigors.

“The primary goal of using this agent is to address pronounced symptoms and provide supportive relief during periods of increased discomfort.”

Quick Fact: Relief for Acute Distress

Quick Fact: Relief for Acute Distress

Meperidine is applied in settings where symptoms require supportive relief, and may help maintain a sense of stability when symptoms are more noticeable, especially in acute care contexts.

Eligibility and Restrictions for Use

Meperidine eligibility is strictly defined by regulatory documents to prevent potentially fatal reactions and toxicity, and use is generally established only for adults. The medicine is contraindicated and must not be used in patients who are taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. Absolute non-eligibility also applies to individuals with acute or severe bronchial asthma, significant respiratory depression, known hypersensitivity to the drug, or documented gastrointestinal obstruction. Use requires extreme caution in older adults due to increased sensitivity and the risk of accumulating the neurotoxic metabolite, normeperidine. It is not recommended for chronic pain and should be avoided in patients with severe renal impairment due to toxicity concerns. Caution is also mandatory for hepatic impairment, head injury, or a history of convulsive disorders. Safety and efficacy are not established in infants under six months of age. During pregnancy, use is limited and generally only permitted when the benefit outweighs the potential risk. The drug is not recommended during lactation as the active substance and its toxic metabolite pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The use of meperidina carries a risk of significant drug-drug interactions, which are strictly documented in regulatory information. The most critical interaction is with Monoamine Oxidase Inhibitors (MAOIs). Concomitant use with MAOIs, or within 14 days of discontinuing MAOI treatment, is contraindicated due to the risk of severe, unpredictable, and potentially fatal reactions, including coma, profound respiratory depression, and features of Serotonin Syndrome.

Clinically Significant Interactions

Meperidina should be used with extreme caution alongside Central Nervous System (CNS) depressants, such as sedatives, hypnotics, tranquilizers, and alcohol, as the combination can result in additive effects, leading to profound sedation, respiratory depression, coma, and death. Reserve such co-prescribing only for patients when alternative options are inadequate.

Concomitant use with other serotonergic drugs (e.g., SSRIs, SNRIs, TCAs, triptans) can precipitate Serotonin Syndrome, a life-threatening condition. Additionally, meperidina is metabolized by Cytochrome P450 enzymes, specifically CYP3A4 and CYP2B6. Use with inhibitors of these enzymes may lead to an increase in meperidina plasma concentrations and enhanced adverse effects, while use with inducers may decrease its efficacy. Use with mixed agonist/antagonist opioid analgesics should be avoided as they may precipitate withdrawal symptoms.

Mechanism of Action

Meperidine functions primarily as an agonist at the mu-opioid receptor (MOR), which is a G protein-coupled receptor (GPCR) predominantly expressed on the cell membranes of neurons in the central nervous system (CNS) and peripheral nervous system.

Upon meperidine binding, the activated MOR couples to inhibitory G proteins (Gi/Go subunits). This coupling initiates intracellular signaling cascades that modulate neuronal excitability. Specifically, the alphai subunit inhibits the enzyme adenylyl cyclase, leading to a decrease in the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP). Simultaneously, the betagamma subunit opens G protein-coupled inwardly rectifying potassium channels (GIRK), causing an efflux of potassium ions (K^+), which hyperpolarizes the neuronal membrane. The betagamma subunit also inhibits voltage-gated calcium channels (primarily N-type), reducing calcium influx (Ca^2+).

Collectively, these actions decrease neuronal firing and neurotransmitter release, particularly in pathways involved in ascending nociceptive transmission. A secondary mechanism involves the inhibition of the neuronal reuptake of serotonin and norepinephrine via interaction with their respective transporters. The system-level consequence of MOR agonism and reuptake inhibition is the modulation of neurotransmission and subsequent alterations in physiological response.

Dosage and Administration Information

The use of Meperidine (Pethidine) is strictly governed by protocols for short-term, acute pain management, with administration reserved for specific clinical needs. Official instructions define the approved routes, dosing ranges, frequency, and maximum limits.

Administration Routes and Dosing

Meperidine is administered through both parenteral (Intramuscular, Subcutaneous, Intravenous) and oral routes (Tablet, Oral Solution).

Usage Context Route Standard Adult Dose Frequency Limit
Acute Pain Relief IM, SC, or PO 50 mg to 150 mg Every 3 to 4 hours, as needed (PRN)
Obstetrical Analgesia IM or SC 50 mg to 100 mg May be repeated at 1- to 3-hour intervals
Preoperative Use IM or SC 50 mg to 100 mg Administered 30 to 90 minutes prior to anesthesia

Administration Guidelines

Administration must adhere to labeled constraints to define the course of treatment:

  • Duration and Maximum: Meperidine is used for acute, time-limited episodes only. The total daily dose must generally not exceed 600 mg in a 24-hour period, with some guidelines advising use for no longer than 48 hours.
  • IV Administration: Intravenous dosing must be administered very slowly, preferably utilizing a diluted solution.
  • Oral Solution Preparation: The oral solution must be diluted in one-half glass of water before swallowing to reduce mucosal effects.
  • Population Adjustments: For older adults and patients with renal or hepatic impairment, the initial dose must be significantly reduced and should be started at the low end of the dosing range (e.g., 25 mg parenterally).

The dosage must be individualized and titrated to the lowest effective level; use is typically limited to the minimum time and dose necessary for the acute scenario.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Meperidina

Evidence for Use in Indication 1 (Hypothetical)

Research exploring Meperidina for conditions characterized by fluctuating or episodic manifestations (Indication 1) has primarily included short-term randomized controlled trials (RCTs) and some observational studies. Research examined whether short-term changes could be measured in outcomes related to physical discomfort using standardized measurement scales. Findings describe patterns observed in severity scale measurements; however, findings were mixed when researchers examined patient-reported outcomes or metrics reflecting daily functioning. Evidence is limited due to modest sample sizes and short follow-up durations, meaning that the results apply only to the specific populations studied.

Evidence for Use in Indication 2 (Hypothetical)

Studies monitoring Meperidina's use in conditions associated with acute or disruptive episodes (Indication 2) were mainly retrospective cohort studies and non-randomized comparative studies. Research examined outcomes describing episodic changes and physiological strain or stress markers. Data show patterns related to how specific physiological markers changed in patients over the study period, but variability was observed. Because the evidence derived from observational settings, it does not establish certainty about the cause of these changes, and there is limited information regarding longer-term functional outcomes.

Long-Term Studies and Follow-Up

The majority of studies evaluating Meperidina are relevant in trials assessing short-term or episodic symptom patterns. Consequently, there is limited information for long-term outcomes extending beyond a few weeks or months. Long-term outcomes are not fully established, meaning that whether the measured short-term changes persist or what patterns emerge over extended periods is still uncertain.

Evidence in Specific Patient Populations

Data for certain groups remain insufficient, as existing research primarily includes general adult populations. Few data are available from studies that monitored outcomes in older adults, children, adolescents, or those who are pregnant or breastfeeding. Comparative evidence is also lacking for many patients with comorbid conditions, making it uncertain how the observed findings would translate to these specific physiological or age-related characteristics.

What Is Still Uncertain About Meperidina

The research conducted so far contributes to the broader evidence landscape but leaves several key areas uncertain. Evidence quality varies across studies, and findings were mixed for several measured outcomes, particularly for patient-reported experiences. Research provides context but not individual predictions. The evidence highlights what is known and what is still uncertain, indicating that the field requires further research, particularly with longer follow-up durations.

Frequently Asked Questions (FAQ)

Common questions about Meperidina (FAQ)

Q: How quickly does Meperidina start working after it's administered?

A: According to official product information, meperidine typically begins to work quickly. The onset of action is generally within 10 to 15 minutes after administration, with the strongest effect (peak) usually occurring about 30 to 50 minutes later.

Q: What is the typical duration of pain relief from a dose of Meperidina?

A: The analgesic (pain-relieving) effect of a single dose of meperidine generally lasts for a relatively short time. The typical duration of pain relief is approximately 2 to 4 hours.

Q: Do people feel 'high' or euphoric when they take Meperidina?

A: Meperidine is an opioid, and like other medications in this class, it can affect the central nervous system. Official safety data notes that it may cause psychomimetic effects such as a feeling of euphoria (intense happiness) or dysphoria (a state of general unease or dissatisfaction).

Q: Can older adults safely use Meperidina, or are there special concerns?

A: Official clinical guidelines often indicate that meperidine may need to be avoided in adults aged 65 and older. This is due to a potentially increased risk of neurotoxicity, which can lead to symptoms like confusion or delirium, compared with some other available pain medications.

Q: Why is Meperidina sometimes used for managing shaking or tremors (shivering)?

A: In addition to pain relief, Meperidine has been noted in clinical settings for its effectiveness in controlling rigors or shivering, particularly following surgical procedures or anesthesia. This specific use is often cited in hospital and critical care protocols.

Q: What should I do if I feel dizzy or lightheaded after getting Meperidina?

A: Meperidine can cause hypotension (low blood pressure), which can result in feelings of dizziness or lightheadedness. Information often indicates that lying down and contacting a healthcare provider may be appropriate if these symptoms persist or worsen.

Q: Is it normal to feel sleepy or drowsy after receiving Meperidina?

A: Yes, sedation and drowsiness are commonly reported side effects of meperidine. Because of this effect, product information advises caution regarding activities requiring mental alertness, such as driving.

Q: Does Meperidina show up on standard drug tests?

A: As a potent, synthetic opioid analgesic and a federally controlled substance, meperidine and its byproducts are typically detectable in standard drug screening tests for opioids.

Q: How is Meperidina different from Morphine in terms of how it works?

A: While both meperidine and morphine work by targeting the same opioid receptors in the brain, meperidine has a distinct secondary action. Meperidine also inhibits the reuptake of chemical messengers known as serotonin and norepinephrine, a mechanism not typically shared by morphine.

Q: What is the risk of having a serious allergic reaction to Meperidina?

A: Meperidine is contraindicated (should not be used) in anyone with a known hypersensitivity (allergy) to the drug. While rare, serious allergic reactions, including potentially life-threatening anaphylaxis, are a possibility and typically warrant medical evaluation.

Q: What is the half-life of Meperidina in the body?

A: The elimination half-life of meperidine itself, which is the time it takes for half the drug to be removed, generally ranges from 3 to 8 hours. However, its major metabolite, normeperidine, has a much longer half-life of around 20 hours.

Q: Why do some people say Meperidina is not used as often anymore compared to other opioids?

A: Meperidine's use has decreased in recent years due to the safety profile associated with its breakdown product, normeperidine. This metabolite can accumulate, particularly with repeated dosing or in certain patients, leading to a higher risk of serious side effects, including seizures.

Q: Why is the drug Meperidina often mentioned in relation to something called 'normeperidine'?

A: Normeperidine is a major, active chemical created when the body processes meperidine. This metabolite can build up in the body and is a central nervous system (CNS) stimulant, meaning it can cause nervous system toxicity leading to symptoms like agitation, tremors, or even seizures.

Q: Can Meperidina be given to children, and if so, for what reasons?

A: Meperidine has established dosing guidelines for acute pain relief in children starting at one year of age. However, due to concerns regarding neurotoxicity from its metabolite, use in children is generally subject to caution in clinical practice.

Q: Is Meperidina safe for people who have kidney issues?

A: The official product information advises caution when meperidine is used in patients with kidney disease. The kidney is responsible for clearing the drug and its toxic metabolite, normeperidine, so impaired kidney function increases the risk of this metabolite building up.

Q: What is the difference between Meperidina tablets and the injection form?

A: The most significant difference is how quickly the drug works and its absorption. The injectable form (parenteral) acts faster than the tablet (oral). Official product information indicates that meperidine is significantly less absorbed when taken by mouth compared to the injection.

Q: What are the signs that someone might be having a bad reaction to Meperidina?

A: Serious adverse reactions include signs of CNS toxicity or respiratory issues. Symptoms like slow or shallow breathing, extreme weakness, severe confusion, hallucinations, or seizures typically warrant seeking prompt medical evaluation.

Q: Are there any known long-term side effects from using Meperidina briefly?

A: While used for short-term pain, official warnings note that brief use of meperidine still carries risks. These include the potential for conditions like Serotonin Syndrome, adrenal insufficiency (marked by severe weakness), and the possibility of developing physical dependence.

Q: Do pregnant people sometimes receive Meperidina during labor?

A: Meperidine has been used for obstetrical analgesia to manage pain during labor and delivery. However, it is known that the drug and its active metabolite can cross the placenta and may cause symptoms of withdrawal in the newborn after delivery.

Q: What kind of pain is Meperidina typically best at treating?

A: Meperidine is formally indicated for the relief of moderate to severe pain. Clinical guidance sometimes notes its utility in managing specific types of pain, such as that associated with certain digestive tract issues, because of its unique effects on smooth muscle.

Q: Can Meperidina cause problems with memory or concentration?

A: Yes, meperidine's effect as a central nervous system (CNS) depressant means it can impair mental and physical abilities. Regulatory documents specifically caution users that the drug may interfere with tasks that require mental alertness, such as driving or operating complex machinery.

Q: Does Meperidina interact with common blood pressure medications?

A: Meperidine carries a warning that it can cause severe hypotension (very low blood pressure). Therefore, caution is advised when it is used in individuals who are already taking medications to lower blood pressure or in patients with conditions like circulatory shock.

Q: Is Meperidina still used in emergency room settings?

A: While its use for general pain has declined, meperidine is still sometimes used in specific emergency and critical care situations. This includes its use to suppress shivering or rigors (uncontrolled shaking), a use for which it is recognized as being effective.

Q: What research shows about Meperidina's role in chronic pain vs. acute pain?

A: Official drug information is clear that meperidine should not be used to treat chronic pain (long-lasting pain). Its approved use is strictly limited to short-term, acute (sudden and severe) pain management.

Q: What does the feeling of 'dry mouth' mean when taking Meperidina?

A: Dry mouth (xerostomia) is listed as a common, recognized side effect of meperidine. Official information notes that this may be managed by simple measures like using sugarless gum or hard candy.

Q: Are there different brand names for Meperidina?

A: Yes, meperidine is recognized by several names globally. In the United States, it is most commonly known by the brand name Demerol. It is also recognized internationally by the name Pethidine.

Q: Can Meperidina affect heart rate?

A: Meperidine can have an effect on the heart rate. It is advised to use it with caution in patients with fast heart rhythms (supraventricular tachycardias) because its action may lead to an increase in the heart's ventricular response rate.

Q: How long does Meperidina stay in your system after the last dose?

A: The amount of time meperidine and its effects persist depends on the clearance of its metabolite, normeperidine. While the drug itself is metabolized relatively quickly, the metabolite remains in the body for much longer, with a half-life of over 20 hours.

Q: What is the typical recovery time after receiving a dose of Meperidina?

A: Because meperidine causes sedation and a measurable impairment of mental abilities, product information suggests caution, and activities that require full attention may need to be avoided until the individual is certain of how the drug affects them.

Q: Does Meperidina have a warning about interaction with St. John's Wort?

A: Official warnings state that meperidine should not be taken with drugs that increase serotonin levels, as this can cause Serotonin Syndrome. St. John's Wort is a supplement that can have serotonergic effects, creating a potential risk for this serious condition.

Q: How does Meperidina interact with common over-the-counter pain relievers like Tylenol?

A: Regulatory sources indicate that the concurrent use of meperidine with acetaminophen (Tylenol) can potentially increase the rate at which meperidine is metabolized by the body. Since acetaminophen also has effects on the central nervous system, caution is generally advised.

How should Meperidina be stored and disposed of?

Storage and Disposal of Meperidine

The storage and disposal of Meperidine (Pethidine) must follow strict regulatory requirements to maintain product stability and ensure public safety.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Avoid freezing.
Protection Store away from excess heat, excess moisture, and direct light.
Container Keep in the original container and ensure it is tightly closed.
Child Safety Must be kept in a secure place and out of the sight and reach of children.

Disposal Instructions

Unused or expired Meperidine must be disposed of promptly to eliminate the risk of accidental ingestion or misuse. The preferred method is to return the medicine to an authorized drug take-back program. If a program is not immediately available, regulatory guidelines permit flushing the tablets or oral solution down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Meperidina found in:

A-Z Index: